Le Lézard
Classified in: Health
Subject: PER

U.S. Dermatology Partners is pleased to welcome Dermatology Nurse Practitioner, Kelsey Mason, to their Lees Summit location


LEES SUMMIT, Mo., Jan. 14, 2021 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to welcome Dermatology Nurse Practitioner Kelsen Mason to its Lees Summit, Missouri office.

Kelsey Mason, NP earned her Master of Science in Nursing ? Family Nurse Practitioner Degree in 2013 from Cox College in Springfield, Missouri where she graduated at the top of her class. Prior to that, she received her Bachelor of Science in Nursing Degree from Truman State University in Kirksville, Missouri in 2010 where she graduated magna cum laude.

After graduating, she practiced internal medicine/pediatrics as a foundation to her eventual goal of exclusively practicing dermatology. She has always had an interest in dermatology and treated a wide variety of skin conditions within the scope of her internal medicine/pediatrics practice. She was initially drawn to dermatology because of her personal experience as a former acne patient, and how its treatment helped to optimize her overall self-confidence as a teenager.

She later became Southern Illinois University Division of Dermatology's first mid-level provider and served as an adjunct faculty member. Kelsey's clinical interests include skin cancer detection and management, acne, rosacea, and psoriasis.

The most rewarding part of her job is providing patient education on the best practices for skincare and developing relationships with her patients in order to customize treatment plans to their specific dermatologic needs. Recognizing the psychosocial impact that dermatological conditions can have on a patient, she seeks every opportunity to improve skin conditions and thereby improve quality of life.

Kelsey is a member of the Sigma Theta Tau International Nursing Honor Society, the Dermatology Nurse Practitioner Society, and the Dermatology Nurses Association.

When not treating patients, Kelsey enjoys lap swimming, traveling, scuba diving, hiking, writing, playing the piano, St. Louis Cardinals baseball, and spending time with friends and family.

To schedule an appointment call 816-524-4747.

About Dermatology and Skin Cancer Centers
Dermatology and Skin Cancer Centers was founded in 1987 by Dr. Glenn Goldstein and was one of the first practices to offer Mohs Micrographic Surgery for high-risk skin cancer patients. Headquartered in the Kansas City area, Dermatology and Skin Cancer Centers, now a part of U.S. Dermatology Partners, is recognized as one of the top treatment centers in the nation for skin cancer prevention, diagnosis, and treatment. Our physician team remains dedicated to the treatment and prevention of skin cancers. Our state-of-the-art facilities are designed with the patient experience in mind and feature the latest technologies and procedures across all areas of dermatology, including general medical dermatology, surgical dermatology, plastic surgery, and cosmetic and aesthetic dermatology.

About U.S. Dermatology Partners
As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners' patients not only have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit http://www.usdermatologypartners.com

Media Contact

Jeanne Cunningham, U.S. Dermatology Partners, 2144200655, [email protected]

 

SOURCE U.S. Dermatology Partners


These press releases may also interest you

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...



News published on and distributed by: